Caribou Biosciences (CRBU) Set to Release Earnings on Wednesday

Caribou Biosciences (NASDAQ:CRBU) is expected to post its Q3 2026 resultson Wednesday, November 11th. Analysts expect Caribou Biosciences to post earnings of ($0.27) per share and revenue of $1.60 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.08. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%. The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.28 million. On average, analysts expect Caribou Biosciences to post ($1.07) EPS for the current fiscal year and ($0.73) EPS for the next fiscal year.

Caribou Biosciences Trading Down 0.3%

NASDAQ CRBU traded down $0.00 on Wednesday, hitting $0.46. 32,315 shares of the company’s stock traded hands, compared to its average volume of 1,894,024. The firm has a market capitalization of $49.10 million, a PE ratio of -0.42 and a beta of 2.50. Caribou Biosciences has a 1-year low of $0.41 and a 1-year high of $2.49. The firm’s 50-day moving average price is $1.02 and its two-hundred day moving average price is $1.62.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on CRBU shares. HC Wainwright lowered Caribou Biosciences from a “buy” rating to a “neutral” rating in a research note on Thursday, October 8th. Wall Street Zen cut shares of Caribou Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Brookline Capital Markets lowered Caribou Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 7th. Royal Bank Of Canada cut shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 target price for the company. in a research note on Wednesday, October 7th. Finally, Leerink Partners lowered Caribou Biosciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $4.00 to $1.00 in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Caribou Biosciences has an average rating of “Hold” and a consensus price target of $4.50.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses CRISPR gene-editing technology to engineer allogeneic, or “off-the-shelf,” immune-cell therapies designed to target cancer cells while reducing limitations associated with individualized cell treatments.

Caribou’s research platform is based on CRISPR hybrid RNA-DNA guide technology, which is intended to support precise and efficient genome editing.